🇺🇸 FDA
Pipeline program

Lixisenatide (AVE0010)

EFC6014

Approved small_molecule completed

Quick answer

Lixisenatide (AVE0010) for Diabetes Mellitus, Type 2 is a Approved program (small_molecule) at Sanofi Pasteur with 3 ClinicalTrials.gov record(s).

Program details

Company
Sanofi Pasteur
Indication
Diabetes Mellitus, Type 2
Phase
Approved
Modality
small_molecule
Status
completed

Clinical trials